$PLSE
PULSE BIOSCIENCES, INC.

2022 Q3 Form 10-Q Financial Statement

#000162510122000061 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $300.0K $444.0K
YoY Change -100.0%
Cost Of Revenue $8.400M $1.344M $909.0K
YoY Change 1055.43%
Gross Profit -$8.400M -$1.044M -$465.0K
YoY Change 5390.2%
Gross Profit Margin -348.0% -104.73%
Selling, General & Admin $5.108M $7.477M $10.04M
YoY Change -33.32% 6.1% 12.04%
% of Gross Profit
Research & Development $4.517M $5.458M $6.769M
YoY Change -30.08% -26.83% -25.31%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K $200.0K
YoY Change 100.0% 100.0% 100.0%
% of Gross Profit
Operating Expenses $4.517M $5.458M $6.769M
YoY Change -30.08% -63.14% -63.46%
Operating Profit -$18.03M -$14.01M -$17.27M
YoY Change 26.29% -5.35% -6.76%
Interest Expense -$14.00K $18.00K $0.00
YoY Change 55.56% -96.52% -100.0%
% of Operating Profit
Other Income/Expense, Net -$14.00K $18.00K $0.00
YoY Change 55.56% -103.48% -100.0%
Pretax Income -$18.04M -$14.00M -$17.27M
YoY Change 26.31% -8.66% -7.33%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$18.04M -$14.00M -$17.30M
YoY Change 26.15% -8.66% -7.18%
Net Earnings / Revenue -4665.33% -3896.4%
Basic Earnings Per Share -$0.49 -$0.44 -$0.58
Diluted Earnings Per Share -$0.49 -$0.44 -$580.7K
COMMON SHARES
Basic Shares Outstanding 37.13M 31.49M 29.80M
Diluted Shares Outstanding 37.16M 31.49M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.16M $14.80M $12.68M
YoY Change 64.71% -68.8% -78.83%
Cash & Equivalents $69.16M $14.80M $12.68M
Short-Term Investments
Other Short-Term Assets $1.244M $1.062M $1.979M
YoY Change -56.59% -67.49% 106.15%
Inventory $750.0K $7.871M $7.487M
Prepaid Expenses
Receivables $5.000K $8.000K $21.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $71.16M $23.74M $22.16M
YoY Change 44.61% -61.56% -64.24%
LONG-TERM ASSETS
Property, Plant & Equipment $2.286M $2.386M $2.554M
YoY Change -6.54% -3.01% 5.1%
Goodwill $2.791M $2.791M $2.791M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $365.0K $365.0K $365.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $16.41M $16.86M $17.37M
YoY Change -8.52% -7.8% -6.51%
TOTAL ASSETS
Total Short-Term Assets $71.16M $23.74M $22.16M
Total Long-Term Assets $16.41M $16.86M $17.37M
Total Assets $87.57M $40.60M $39.53M
YoY Change 30.41% -49.28% -50.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.022M $1.948M $3.486M
YoY Change -25.28% -31.0% 61.09%
Accrued Expenses $3.982M $4.757M $4.604M
YoY Change -19.9% 4.05% -18.03%
Deferred Revenue $38.00K $32.00K $16.00K
YoY Change 442.86%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $98.00K $0.00 $0.00
YoY Change -90.98% -100.0% -100.0%
Total Short-Term Liabilities $6.998M $7.564M $8.905M
YoY Change -26.48% -23.16% 4.42%
LONG-TERM LIABILITIES
Long-Term Debt $65.00M $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $9.383M $9.618M $9.833M
YoY Change -8.39% -7.92% -7.5%
Total Long-Term Liabilities $74.38M $9.618M $9.833M
YoY Change 626.25% -7.92% -80.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.998M $7.564M $8.905M
Total Long-Term Liabilities $74.38M $9.618M $9.833M
Total Liabilities $81.38M $17.18M $18.74M
YoY Change 311.83% -15.31% -68.85%
SHAREHOLDERS EQUITY
Retained Earnings -$285.5M -$267.5M -$253.5M
YoY Change 29.31% 29.54% 32.6%
Common Stock $291.7M $290.9M $274.3M
YoY Change 8.77% 9.25% 29.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.189M $23.42M $20.80M
YoY Change
Total Liabilities & Shareholders Equity $87.57M $40.60M $39.53M
YoY Change 30.41% -49.28% -50.92%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$18.04M -$14.00M -$17.30M
YoY Change 26.15% -8.66% -7.18%
Depreciation, Depletion And Amortization $200.0K $200.0K $200.0K
YoY Change 100.0% 100.0% 100.0%
Cash From Operating Activities -$10.63M -$12.82M -$15.60M
YoY Change -20.36% -21.64% 33.48%
INVESTING ACTIVITIES
Capital Expenditures -$62.00K -$19.00K $279.0K
YoY Change -60.51% -80.21% 447.06%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$62.00K -$19.00K -$279.0K
YoY Change -60.51% -80.21% -103.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 65.06M 14.96M -65.00K
YoY Change 705.97% 273.89% -100.13%
NET CHANGE
Cash From Operating Activities -10.63M -12.82M -15.60M
Cash From Investing Activities -62.00K -19.00K -279.0K
Cash From Financing Activities 65.06M 14.96M -65.00K
Net Change In Cash 54.36M 2.122M -15.94M
YoY Change -1100.26% -117.03% -133.62%
FREE CASH FLOW
Cash From Operating Activities -$10.63M -$12.82M -$15.60M
Capital Expenditures -$62.00K -$19.00K $279.0K
Free Cash Flow -$10.57M -$12.80M -$15.88M
YoY Change -19.88% -21.29% 35.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Address Line1
EntityAddressAddressLine1
3957 Point Eden Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
906-4600
CY2021Q4 us-gaap Inventory Net
InventoryNet
5824000
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
PLSE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37125947
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14798000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28614000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
61000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1062000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2131000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
23739000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36630000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2386000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2462000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2883000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3216000
CY2022Q2 us-gaap Goodwill
Goodwill
2791000
CY2021Q4 us-gaap Goodwill
Goodwill
2791000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8433000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8785000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Central Index Key
EntityCentralIndexKey
0001625101
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2904000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4757000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34899
dei Entity Registrant Name
EntityRegistrantName
Pulse Biosciences, Inc.
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4389000
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5696597
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
365000
CY2022Q2 us-gaap Inventory Net
InventoryNet
7871000
CY2022Q2 us-gaap Assets
Assets
40597000
CY2021Q4 us-gaap Assets
Assets
54249000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1948000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
1344000
us-gaap Cost Of Revenue
CostOfRevenue
2253000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
827000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
436000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7564000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8519000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9618000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10040000
CY2022Q2 us-gaap Liabilities
Liabilities
17182000
CY2021Q4 us-gaap Liabilities
Liabilities
18559000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37126000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37126000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29716000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29716000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
37000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290847000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
271861000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267469000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-236200000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23415000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
35690000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40597000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54249000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
265000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
7293000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3787000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5458000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7459000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12227000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16522000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26477000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26477000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30623000
CY2022Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3690000
CY2021Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3147000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
9231000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4200000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8285000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9516000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
14279000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
14806000
us-gaap Costs And Expenses
CostsAndExpenses
31996000
us-gaap Costs And Expenses
CostsAndExpenses
33331000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14014000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14806000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31287000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33331000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-517000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-631000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-517000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-631000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13996000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15323000
us-gaap Net Income Loss
NetIncomeLoss
-31269000
us-gaap Net Income Loss
NetIncomeLoss
-33962000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13996000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15323000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31269000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33961000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31492000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31492000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
232000
us-gaap Repayments Of Debt
RepaymentsOfDebt
437000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30623000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26276000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26276000
us-gaap Net Income Loss
NetIncomeLoss
-31269000
us-gaap Net Income Loss
NetIncomeLoss
-33962000
us-gaap Depreciation
Depreciation
347000
us-gaap Depreciation
Depreciation
229000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
333000
us-gaap Share Based Compensation
ShareBasedCompensation
3720000
us-gaap Share Based Compensation
ShareBasedCompensation
9413000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-13000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-53000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2047000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2691000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1112000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2454000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
30000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-23000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-352000
plse Noncash Adjustment Right Of Use Assets
NoncashAdjustmentRightOfUseAssets
-319000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-931000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1041000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
296000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-754000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-369000
plse Noncash Adjustment Lease Liabilities
NoncashAdjustmentLeaseLiabilities
-192000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
629000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28416000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28053000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
146000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-298000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7854000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
372000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
421000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4217000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
678000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14963000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48348000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1730000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14898000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55162000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7432000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-13816000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
34963000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28614000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12463000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14798000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47426000
plse Increase Decrease In Equipment Purchases Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
-27000
plse Increase Decrease In Equipment Purchases Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInEquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses
65000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
1000
us-gaap Stock Issued1
StockIssued1
629000
plse Other Related Party Receivable From Issuance Of Common Stock
OtherRelatedPartyReceivableFromIssuanceOfCommonStock
8371000
plse Other Receivable From Issuance Of Common Stock
OtherReceivableFromIssuanceOfCommonStock
13000
plse Other Receivable From Issuance Of Common Stock
OtherReceivableFromIssuanceOfCommonStock
25000
plse Stock Issuance Costs Accrued
StockIssuanceCostsAccrued
-74000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
20796000
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
111000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14889000
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1713000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13996000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23415000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
35690000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
111000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14889000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
372000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3720000
us-gaap Net Income Loss
NetIncomeLoss
-31269000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23415000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
20397000
CY2021Q2 plse Payment Of Stock Issuance And Debt Extinguishment Costs
PaymentOfStockIssuanceAndDebtExtinguishmentCosts
59000
CY2021Q2 plse Issuance Of Common Stock As Part Of Debt Extinguishment And Private Investment Net Of Issuance Cost
IssuanceOfCommonStockAsPartOfDebtExtinguishmentAndPrivateInvestmentNetOfIssuanceCost
49941000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2469000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
59000
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-232000
CY2021Q2 plse Adjustment To Shares Issued Under Employee Stock Purchase Plan Value
AdjustmentToSharesIssuedUnderEmployeeStockPurchasePlanValue
-9000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2448000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-15323000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22894000
plse Payment Of Stock Issuance And Debt Extinguishment Costs
PaymentOfStockIssuanceAndDebtExtinguishmentCosts
59000
plse Issuance Of Common Stock As Part Of Debt Extinguishment And Private Investment Net Of Issuance Cost
IssuanceOfCommonStockAsPartOfDebtExtinguishmentAndPrivateInvestmentNetOfIssuanceCost
49941000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3334000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
508000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
421000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
255000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
513000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-232000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9413000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Net Income Loss
NetIncomeLoss
-33962000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
59750000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28400000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
14800000
us-gaap Net Income Loss
NetIncomeLoss
-31300000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
82000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-align: justify;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the Financial Statements and accompanying notes to the condensed consolidated financial statements. Estimates include, but are not limited to, the valuation of cash equivalents, the valuation and recognition of share-based compensation, inventory valuation, warranty obligations, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
200000
CY2022Q1 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
97000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
80000
CY2022Q2 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
25000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
42000
CY2022Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
122000
CY2022Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
122000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12919057
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5917397
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13502000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23675000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
plse Fair Value Equity Level12 And3 Transfers Amount
FairValueEquityLevel12And3TransfersAmount
0
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4757000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4389000
CY2022Q2 us-gaap Restructuring Reserve
RestructuringReserve
200000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
265000
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3497000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2010000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1788000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1371000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2586000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2443000
CY2022Q2 us-gaap Inventory Net
InventoryNet
7871000
CY2021Q4 us-gaap Inventory Net
InventoryNet
5824000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5129000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4858000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2743000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2396000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2386000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2462000
CY2022Q2 us-gaap Depreciation
Depreciation
200000
CY2021Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
200000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
CY2022Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
122000
CY2021Q4 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
80000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7985000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5102000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4769000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2883000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3216000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
332000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
665000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
665000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
665000
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
556000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2883000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3695000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2932000
CY2022Q2 plse Controlled Launch
ControlledLaunch
267000
CY2021Q4 plse Controlled Launch
ControlledLaunch
534000
CY2022Q2 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
134000
CY2021Q4 plse Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
245000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
202000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
85000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
265000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
709000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1713000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2448000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3720000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9413000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1713000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2448000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3720000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9413000
CY2021Q2 plse Director And Officer Insurance Premium Payable
DirectorAndOfficerInsurancePremiumPayable
2600000
CY2021Q2 plse Insurance Down Payment
InsuranceDownPayment
700000
CY2021Q2 plse Financed Insurance Policy Balance
FinancedInsurancePolicyBalance
1900000
CY2021Q2 plse Financed Insurance Policy Interest Rate
FinancedInsurancePolicyInterestRate
0.0369
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
700000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
911000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1845000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1910000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1977000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2046000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6191000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14880000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4435000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
10445000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
827000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9618000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
10445000
us-gaap Operating Lease Payments
OperatingLeasePayments
894000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M2D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
plse Number Of Kols
NumberOfKols
70
plse Number Of Patients Participating In Procedure
NumberOfPatientsParticipatingInProcedure
40 or 50
CY2022Q2 plse Program Expenses
ProgramExpenses
100000
CY2021Q2 plse Program Expenses
ProgramExpenses
400000
plse Program Expenses
ProgramExpenses
600000
plse Program Expenses
ProgramExpenses
600000
CY2022Q2 plse Controlled Launch Revenue Recognized
ControlledLaunchRevenueRecognized
100000
plse Controlled Launch Revenue Recognized
ControlledLaunchRevenueRecognized
400000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
300000
CY2022Q1 us-gaap Restructuring Reserve
RestructuringReserve
700000
CY2022Q2 us-gaap Payments For Restructuring
PaymentsForRestructuring
500000
CY2022Q2 us-gaap Restructuring Reserve
RestructuringReserve
200000

Files In Submission

Name View Source Status
0001625101-22-000061-index-headers.html Edgar Link pending
0001625101-22-000061-index.html Edgar Link pending
0001625101-22-000061.txt Edgar Link pending
0001625101-22-000061-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plse-20220630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
plse-20220630_cal.xml Edgar Link unprocessable
plse-20220630x10q.htm Edgar Link pending
plse-20220630xex10_1.htm Edgar Link pending
plse-20220630xex31_1.htm Edgar Link pending
plse-20220630xex31_2.htm Edgar Link pending
plse-20220630xex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
plse-20220630_def.xml Edgar Link unprocessable
plse-20220630_lab.xml Edgar Link unprocessable
plse-20220630_pre.xml Edgar Link unprocessable
plse-20220630x10q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending